Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18808138 | Compositions and Methods for Treating Endocrine Diseases and Disorders | August 2024 | October 2024 | Allow | 2 | 0 | 0 | No | No |
| 18396499 | COMPOSITION CONTAINING HIGHLY UNSATURATED FATTY ACID OR ALKYL ESTER THEREOF AND A METHOD FOR PRODUCING THE SAME | December 2023 | November 2024 | Allow | 11 | 1 | 0 | No | No |
| 18390964 | NUTRITIONAL COMPOSITIONS FROM BREWERS' SPENT GRAIN AND METHODS FOR MAKING THE SAME | December 2023 | June 2024 | Allow | 5 | 1 | 0 | No | No |
| 18558067 | AMAROUCIAXANTHIN A ESTERS AND USES THEREOF | October 2023 | June 2024 | Allow | 7 | 0 | 0 | No | No |
| 18241641 | SALTS OF TREPROSTINIL | September 2023 | February 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18023293 | VINYL ACETATE PRODUCTION PROCESS AND DEVICE | February 2023 | December 2024 | Abandon | 21 | 2 | 0 | No | No |
| 18150464 | IONIZABLE LIPID COMPOUNDS | January 2023 | July 2024 | Allow | 19 | 1 | 1 | No | No |
| 17984331 | DOCOSAHEXAENOIC ACID-CONTAINING OIL AND METHOD FOR PRODUCING SAME | November 2022 | September 2024 | Allow | 22 | 2 | 0 | No | No |
| 17943512 | METHOD OF OIL EXTRACTION | September 2022 | January 2025 | Abandon | 28 | 2 | 0 | No | No |
| 17781394 | PROCESS FOR THE CONTINUOUS PREPARATION OF HEAVY ALKYL ACRYLATES | June 2022 | January 2025 | Allow | 32 | 0 | 0 | No | No |
| 17723537 | METHOD AND SYSTEM FOR PRODUCING A PROTEIN AND FIBER FEED PRODUCT FROM A WHOLE STILLAGE BYPRODUCT PRODUCED IN A CORN DRY MILLING PROCESS | April 2022 | September 2024 | Allow | 29 | 2 | 0 | No | No |
| 17584818 | METHOD FOR PURIFYING PHOSPHORUS-CONTAINING OLEFIN COMPOUND SALT AND METHOD FOR PRODUCING OLEFIN COMPOUND USING PURIFIED PRODUCT OBTAINED THEREBY | January 2022 | January 2025 | Allow | 36 | 1 | 1 | No | No |
| 17545747 | PROCESS FOR PURIFYING LPC-DHA AND/OR LPC-EPA USING A CHROMATOGRAPHIC STATIONARY PHASE AND COMPOSITIONS THEREOF | December 2021 | August 2024 | Allow | 32 | 1 | 0 | No | No |
| 17614353 | METHOD OF EXTRACTING POLYHYDROXYLATED FATTY ALCOHOLS USING SUPERCRITICAL CO2 | November 2021 | May 2024 | Allow | 30 | 1 | 0 | No | No |
| 17595736 | AN OIL EXTRACT COMPRISING DIHOMOLINOLENIC ACID, AND A PROCESS FOR PRODUCING THE OIL EXTRACT | November 2021 | January 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17367548 | ORGANIC BASED EXTRACTION SYSTEM | July 2021 | January 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17413584 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CUTANEOUS T CELL LYMPHOMA (CTCL) | June 2021 | February 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17296742 | META-DIAMIDE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS | May 2021 | October 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17324745 | COMPOSITIONS FOR FEEDING A PREGNANT ANIMAL | May 2021 | September 2024 | Allow | 40 | 1 | 0 | No | No |
| 17227786 | COMPOSITIONS AND METHODS FOR MODULATION OF EXTRACELLULAR VESICLE RELEASE AND TREATMENT OF NEUROLOGICAL DISORDERS | April 2021 | September 2024 | Allow | 41 | 1 | 0 | No | No |
| 17282587 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING LEBER'S HEREDITARY OPTIC NEUROPATHY | April 2021 | October 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17280092 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES AND/OR DISORDERS CAUSED BY EXPOSURE TO AIR POLLUTION | March 2021 | December 2024 | Abandon | 45 | 1 | 0 | No | No |
| 17301076 | LEUCINE-ENRICHED KETOGENIC FORMULATIONS | March 2021 | November 2024 | Allow | 44 | 1 | 0 | No | No |
| 17275576 | METHODS OF REDUCING THE NEED FOR PERIPHERAL ARTERIAL REVASCULARIZATION IN A STATIN-TREATED SUBJECT | March 2021 | November 2024 | Abandon | 44 | 1 | 0 | No | No |
| 17250841 | A CATALYST AND ITS USE IN FATTY ACID ISOMERISATION | March 2021 | June 2024 | Allow | 39 | 1 | 2 | No | No |
| 17273643 | CANNABIDIOL COMPOSITIONS HAVING MODIFIED CANNABINOID PROFILES | March 2021 | June 2024 | Allow | 39 | 1 | 0 | No | No |
| 17273034 | METHODS OF TREATING MYCOBACTERIAL INFECTIONS USING TETRACYCLINE COMPOUNDS | March 2021 | June 2024 | Allow | 39 | 1 | 0 | No | No |
| 17182794 | INTERMITTENT ENDURANCE CAPACITY IMPROVING AGENT OR BLOOD pH ELEVATING AGENT | February 2021 | October 2024 | Allow | 44 | 2 | 0 | No | No |
| 17269751 | Applications of Known and Novel Cannabinoids | February 2021 | November 2024 | Allow | 45 | 1 | 1 | No | No |
| 17056069 | COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT | November 2020 | November 2024 | Allow | 48 | 2 | 0 | No | No |
| 17013919 | COMPOUNDS THAT MODULATE FATTY ACID RECEPTOR ACTIVITY AND PET FOOD PRODUCTS CONTAINING THE SAME | September 2020 | September 2024 | Allow | 48 | 1 | 1 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner CARR, DEBORAH D works in Art Unit 1692 and has examined 19 patent applications in our dataset. With an allowance rate of 63.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.
Examiner CARR, DEBORAH D's allowance rate of 63.2% places them in the 23% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by CARR, DEBORAH D receive 1.05 office actions before reaching final disposition. This places the examiner in the 11% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by CARR, DEBORAH D is 42 months. This places the examiner in the 18% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
When applicants file an RCE with this examiner, 50.0% of applications are subsequently allowed. This success rate is in the 96% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
When applicants file petitions regarding this examiner's actions, 200.0% are granted (fully or in part). This grant rate is in the 98% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 4% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.